Although traditional Notch/γ-secretase inhibitors (GSI) hold great promise for the treatment of cancer and associated therapy resistance, their clinical approval has been hampered by
serious side effects. Our breakthrough technology allowed for the development of FTX-312 and FTX-361, first-in-class prodrugs that release Notch inhibitors exclusively in tumors through an hypoxia dependent mechanism (HyGSI), -a tumor selective characteristic- thereby minimizing side effects and protecting healthy tissue. Preclinical data demonstrates tumor-specific activation and Notch inhibition without side effects, marking a significant advancement in targeted cancer therapy. Within the Biotech Booster program we will further the development of our HyGSI technology, establish Fenix Therapeutics, and advance the clinical development of these therapies, with an initial focus on Triple Negative Breast Cancer, an incurable disease causing 25,000 EU deaths annually. Strategically, the mechanism of action of HyGSI allows us to target hypoxia and Notch-driven therapy resistance across a wide range of malignancies positioning us to address significant unmet medical needs, unlocking new market opportunities and accelerating our mission to bring safe and effective oncology therapeutics to patients.
